- Ambrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment
- Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC)
- Camizestrant significantly delayed disease progression in advanced ER-positive breast cancer, adding at least 3.5 months benefit versus Faslodex
- Capivasertib plus Faslodex reduced the risk of disease progression or death by 40% versus Faslodex in advanced HR-positive breast cancer
- Carrick Therapeutics Presents Encouraging Clinical Data for Samuraciclib (CT7001)
- Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer
- Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer
- Datopotamab deruxtecan showed promising responses as monotherapy and in combination with Imfinzi in patients with mTNBC in two early trials
- Datopotamab deruxtecan showed encouraging and durable efficacy in patients with heavily pretreated HR-positive, HER2-low or negative metastatic breast cancer
- Enhertu achieved statistically significant overall survival, reducing the risk of death by 36% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer in DESTINY-Breast03
- Incyte Announces Data From Two LIMBER Studies Evaluating Combination Treatments In Patients With Myelofibrosis (MF)
- Intensity Therapeutics’ Reports Up to 100% Tumor Necrosis After One Dose of Lead Asset, INT230-6 in Phase 2 INVINCIBLE Neoadjuvant Breast Cancer Study
- Menarini Group Presents Updated Results from Pivotal Phase 3 EMERALD Trial that Demonstrate Elacestrant’s PFS Increases with Duration of Prior CDK4/6i in ER+, HER2- in Metastatic Setting
- New Clinical Data For Zanidatamab In HER2+ /HR+ Metastatic Breast Cancer Presented
- Novartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy
- Olema Oncology Announces OP-1250 Demonstrates Attractive Combinability with CDK 4/6 Inhibitor Palbociclib in Phase 1b Dose Escalation Study
- OncoHealth Presents real-world data research on Off-Label Trastuzumab Deruxtecan and Use in Breast Cancer Brain Metastases
- Trodelvy® Demonstrates Clinical Benefit for Black Patients Consistent with Full mTNBC Population in ASCENT Study
